Hill N C, Selinger M, Ferguson J, MacKenzie I Z
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Headington, UK.
Hum Reprod. 1991 Mar;6(3):458-62. doi: 10.1093/oxfordjournals.humrep.a137358.
The maternal and fetal endocrine effects of the maternal administration of the anti-progestin mifepristone in mid-pregnancy have been investigated. Mifepristone and the metabolite RU 42,633 were detected in the fetal circulation and in the amniotic fluid 4, 24 and 48 h after oral ingestion. Maximum fetal plasma concentrations of mifepristone occurred 4 h after treatment indicating rapid placental transfer of the drug. No significant changes in progesterone, cortisol, oestradiol or aldosterone concentrations were detected in the maternal circulation after mifepristone treatment. No significant changes occurred in the fetal progesterone, oestradiol or cortisol concentrations, but a significant increase in fetal aldosterone occurred 4 and 24 h after treatment. The significance of these results is discussed in relation to the possible therapeutic uses of mifepristone for inducing labour.
已对孕中期母体给予抗孕激素米非司酮对母胎内分泌的影响进行了研究。口服米非司酮后4小时、24小时和48小时，在胎儿循环和羊水中检测到了米非司酮及其代谢产物RU 42,633。治疗后4小时米非司酮在胎儿血浆中的浓度达到最高，表明该药可经胎盘快速转运。米非司酮治疗后，母体循环中孕酮、皮质醇、雌二醇或醛固酮浓度未检测到显著变化。胎儿孕酮、雌二醇或皮质醇浓度也未发生显著变化，但治疗后4小时和24小时胎儿醛固酮显著增加。结合米非司酮诱导分娩的可能治疗用途对这些结果的意义进行了讨论。
